Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Capivasertib‒fulvestrant combo delays second progression, chemo in advanced breast cancer
The addition of capivasertib to fulvestrant improves time to second progression (PFS2) and time to first subsequent chemotherapy or death (TTFSC) in PIK3CA/AKT1/PTEN-altered patients with HR+/HER2- advanced breast cancer and the overall population, suggesting a clinically meaningful benefit when compared with placebo plus fulvestrant, as shown in the phase III CAPItello-291 trial.
Capivasertib‒fulvestrant combo delays second progression, chemo in advanced breast cancer
20 May 2026
Lecanemab continues to delay progression in AD at 4 years
The 48-month analysis of the global phase III Clarity AD study shows that lecanemab continues to deliver benefit and delay progression in early Alzheimer's disease (AD).
Lecanemab continues to delay progression in AD at 4 years
20 May 2026
Lower socioeconomic status tied to poorer RA outcomes
Patients with rheumatoid arthritis (RA) who are living in areas with disadvantageous socioeconomic status (SES) appear to have higher disease activity, disability, and poorer quality of life (QOL), as shown in a study in Australia.
Lower socioeconomic status tied to poorer RA outcomes
19 May 2026
Standard vs custom-made post-mastectomy prosthesis: Which is better?
A study presented at ESMO Breast Cancer 2026 shows that a custom-made external breast prosthesis has a slight advantage over a standard prosthesis among breast cancer patients who have undergone mastectomy.
